ociperlimab + tislelizumab

**Ociperlimab + tislelizumab** is an investigational, intravenously administered dual immune-checkpoint-blockade regimen developed by BeOne Medicines. It combines ociperlimab, a humanized IgG1 anti-TIGIT monoclonal antibody, with tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody. The regimen is intended to restore antitumor T-cell and natural-killer-cell activity by concurrently blocking TIGIT- and PD-1-mediated inhibitory signaling. It has been evaluated across solid tumors, including non-small cell lung cancer, cervical cancer, esophageal squamous cell carcinoma, diffuse large B-cell lymphoma, limited-stage small cell lung cancer, and malignant pleural mesothelioma. It is not a marketed fixed-dose product; the two antibodies are administered as separate intravenous infusions. In April 2025, BeOne discontinued ociperlimab development for lung cancer after a planned futility analysis of the Phase 3 AdvanTIG-302 trial indicated the study was unlikely to meet its overall-survival endpoint. ([ir.beonemedicines.com](https://ir.beonemedicines.com/news/beigene-announces-first-patient-dosed-in-global-phase-3-trial-of-anti-tigit-antibody-ociperlimab-in/bded2be3-a3a5-4f06-b5f3-c4681eea8545))

Brand names

tislelizumabociperlimab

Other names

BGB-A1217 + BGB-A317BGB-A317 + BGB-A1217ociperlimab + tislelizumabtislelizumab + ociperlimab